FDA completed cardiovascular outcomes trials for all four US-approved DPP-4 inhibitors and it was found that all DPP-4 inhibitors possess a neutral impact on microvascular and macrovascular events except saxagliptin, which might elevate the heart failure risk. The gene discussed is DPP4; the disease is heart failure.